SCHEMBL4355476

SCHEMBL4355476

O=C(Nc1ccc2c(c1)OCO2)Nc1cc(Cl)cc(Cl)c1O

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 13/20 0.73
RAB9A P51151 13/20 0.73
KMT2A Q03164 9/20 0.73
SMN1; SMN2 Q16637 6/20 0.73
MAPT P10636 5/20 0.73
GRIK1 P39086 1/20 0.65
MEN1 O00255 7/20 0.65
POLB P06746 2/20 0.65
LMNA P02545 2/20 0.63
MAPK1 P28482 1/20 0.63
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
PKM P14618 1/20 0.57
HTT P42858 1/20 0.55
CNR1 P21554 1/20 0.54
KDM4E B2RXH2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6225028 0.90 RAB9A (0.76) NPC1RAB9AKMT2ASMN1; SMN2MAPT
SCHEMBL4347965 0.85 NPC1 (0.74) NPC1RAB9AKMT2ASMN1; SMN2MAPT
SCHEMBL4352892 0.85 RAB9A (0.67) NPC1RAB9AKMT2ASMN1; SMN2MAPT
SCHEMBL4351428 0.84 RAB9A (0.59) NPC1RAB9AKMT2ASMN1; SMN2MAPT
SCHEMBL4345510 0.84 RAB9A (0.75) NPC1RAB9AKMT2ASMN1; SMN2MAPT
SCHEMBL4342082 0.82 NPC1 (0.62) NPC1RAB9AKMT2ASMN1; SMN2MAPT
SCHEMBL107421 0.81 RAB9A (1.00) NPC1RAB9AKMT2ASMN1; SMN2MAPT
SCHEMBL4354382 0.80 CCR2 (0.75) NPC1RAB9AKMT2ASMN1; SMN2MAPT
SCHEMBL4348490 0.80 GRIK1 (0.59) NPC1RAB9AKMT2ASMN1; SMN2MAPT
SCHEMBL3964569 0.79 GRIK1 (1.00) NPC1RAB9AKMT2ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 NPC1 815/4885RAB9A 4228/4885KMT2A 2096/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 NPC1 1189/4885RAB9A 4588/4885KMT2A 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.